<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03179878</url>
  </required_header>
  <id_info>
    <org_study_id>SYNB1020-CP-001</org_study_id>
    <nct_id>NCT03179878</nct_id>
  </id_info>
  <brief_title>Safety and Tolerability of SYNB1020-CP-001</brief_title>
  <acronym>SYNB1020CP001</acronym>
  <official_title>A Phase 1, First-in-human, Oral Single and Multiple Dose-Escalation, Randomized, Double-blinded, Placebo-controlled Study of SYNB1020 in Healthy Adult Volunteers to Evaluate Safety, Tolerability, Dosing, and Pharmacodynamics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Synlogic</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Synlogic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase 1, First-in-human, Oral Single and Multiple Dose-Escalation, Randomized,&#xD;
      Double-blinded, Placebo-controlled Study of SYNB1020 in Healthy Adult Volunteers to Evaluate&#xD;
      Safety, Tolerability, Dosing, and Pharmacodynamics&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This Phase 1, dose-escalating, randomized, double-blinded study will evaluate SYNB1020 in&#xD;
      placebo-controlled cohorts within the following 2 study parts:&#xD;
&#xD;
      Part 1: A single-ascending dose (SAD) study conducted in an inpatient setting over 6 days in&#xD;
      healthy volunteer male and female subjects evaluated in up to 7 dose cohorts to identify the&#xD;
      maximum tolerated dose (MTD) within the single dose range studied; and Part 2: A&#xD;
      multiple-ascending dose (MAD) study conducted in an inpatient setting over 22 days in healthy&#xD;
      volunteer male and female subjects evaluated in up to 4 dose cohorts that were proven&#xD;
      tolerable in the SAD part of the study to identify the MTD of SYNB1020 within the&#xD;
      multiple-dose range studied. Up to 48 subjects may be enrolled in this part of the study.&#xD;
&#xD;
      Subjects will be screened for eligibility within 30 days prior to enrollment, with&#xD;
      evaluations of exercise habits, gastrointestinal (GI) signs and symptoms, fecal patterns&#xD;
      (frequency, consistency), recent or current antibiotic exposure, and laboratory measurements.&#xD;
      Eligible patients will be admitted to an inpatient facility for investigational product (IP)&#xD;
      administration, safety monitoring, and collection of blood, urine, and fecal samples for&#xD;
      pharmacokinetic and pharmacodynamic evaluations.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 16, 2017</start_date>
  <completion_date type="Actual">April 11, 2018</completion_date>
  <primary_completion_date type="Actual">November 2, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized, Double-blinded, Placebo controlled</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Double Blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events, Laboratory Assessments and ECGs to measure Safety and Tolerability of SYNB1020</measure>
    <time_frame>3 months from study entry</time_frame>
    <description>Will be measured by assessing nature and frequency of AEs, Laboratory Assessments, and ECGs</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>GI tolerability measured using the Gastrointestinal Symptom Rating Scale (GSRS)</measure>
    <time_frame>1 month of study entry</time_frame>
    <description>Will be measured using the Gastrointestinal Symptom Rating Scale (GSRS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SYNB1020 kinetics measured by qPCR fecal assays</measure>
    <time_frame>3 months from study entry</time_frame>
    <description>Will be measured by qPCR fecal assays</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">52</enrollment>
  <condition>Healthy Volunteer</condition>
  <condition>Urea Cycle Disorder</condition>
  <arm_group>
    <arm_group_label>SYNB1020</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SYNB1020</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>100 mL masking solution</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SYNB1020</intervention_name>
    <description>Investigational Product</description>
    <arm_group_label>SYNB1020</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Age 18 to 64 years&#xD;
&#xD;
          -  Healthy volunteer Males and Females; Females must be of non childbearing potential&#xD;
&#xD;
          -  Able and willing to complete informed consent process&#xD;
&#xD;
          -  Available for and agree to all study procedures&#xD;
&#xD;
          -  Screening Labs within normal range&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Acute or chronic medical, surgical, psychiatric, social or laboratory abnormality&#xD;
&#xD;
          -  Body mass index &lt; 18.5 or â‰¥ 30 kg/m2&#xD;
&#xD;
          -  Intolerance of or allergic reaction to E. coli Nissle or any of the ingredients in&#xD;
             SYNB1020 or placebo formulations; allergies to common foods (e.g., eggs, milk, soy,&#xD;
             nuts).&#xD;
&#xD;
          -  Prior participation in a study with SYNB1020&#xD;
&#xD;
          -  Evidence or history of clinical signification hematological, renal, endocrine,&#xD;
             pulmonary, GI cardiovascular, hepatic, psychiatric, neurologic or allergic disease&#xD;
&#xD;
          -  Personal or family history of UCD&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Parexel</name>
      <address>
        <city>Brooklyn</city>
        <state>Maryland</state>
        <zip>21225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>June 6, 2017</study_first_submitted>
  <study_first_submitted_qc>June 6, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 7, 2017</study_first_posted>
  <last_update_submitted>May 11, 2021</last_update_submitted>
  <last_update_submitted_qc>May 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urea Cycle Disorders, Inborn</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

